What Is TB-500? Complete Research Guide (2026)
TB-500 is one of the most consistently studied research peptides in the tissue repair space. It shows up in cardiac research, wound healing studies, muscle injury models, tendon research, and neurological investigations — sometimes in the same published paper. That range of research applications isn’t coincidental. It reflects something specific about TB-500’s mechanism that distinguishes it from most other compounds in the same general category.
This guide covers what TB-500 actually is at a molecular level, where it comes from, how it works, what the published preclinical research shows across different tissue types, how it differs from BPC-157, and what the current regulatory picture looks like in 2026.
What Is TB-500?
TB-500 is a synthetic peptide corresponding to the actin-binding domain of Thymosin Beta-4, a 43-amino acid protein found in virtually every nucleated cell in the human body. The specific fragment used in research — with the sequence Ac-LKKTETQ — corresponds to amino acids 17 through 23 of the full Thymosin Beta-4 molecule.
The Ac- prefix in that sequence indicates the leucine end is acetylated, a structural modification that slows enzymatic breakdown and extends the peptide’s stability in biological environments.
A few things about this origin are worth understanding clearly.
Thymosin Beta-4 itself is not a foreign or synthetic compound — it’s a protein the human body produces naturally and maintains in high concentrations in blood platelets, wound fluid, and essentially every cell with a nucleus. It was first isolated from thymic tissue in the 1960s and has been a subject of scientific investigation for over five decades. The research base supporting the parent molecule is substantially larger than that directly examining the TB-500 fragment.
TB-500 isolates what researchers have identified as the most biologically active region of Thymosin Beta-4 — the actin-binding domain responsible for most of its downstream signaling effects on cell migration and tissue repair.
Compound specifications:
| Property | Detail |
|---|---|
| Common name | TB-500 |
| Full name | Thymosin Beta-4 fragment |
| Amino acid sequence | Ac-LKKTETQ |
| Amino acids | 7 (active fragment of 43-AA Tβ4) |
| Origin | Synthetic analog of endogenous Thymosin Beta-4 |
| Molecular weight | ~844 Da |
| Supplied form | Lyophilized powder |
| Vial size | 5mg (standard research quantity) |
| Storage (lyophilized) | -20°C, up to 24 months |
| Storage (reconstituted) | 2–8°C, up to 28 days |
| CAS number | 77591-33-4 |
TB-500 vs. Full Thymosin Beta-4 — An Important Distinction
This distinction gets consistently blurred in popular coverage of this compound, and it matters for researchers evaluating the literature.
The full Thymosin Beta-4 protein — all 43 amino acids — is the molecule that appears in the majority of published preclinical studies. TB-500, the 7-amino acid fragment, retains the actin-binding motif that drives most of Tβ4’s biological activity but does not contain other structural domains of the parent molecule.
In practical research terms, TB-500 is studied as a more accessible and more stable research tool than the full-length protein. The full protein’s larger size creates stability and bioavailability challenges that the shorter fragment sidesteps. Whether the fragment replicates all of the full molecule’s biological activity is itself a research question that hasn’t been definitively answered.
When reading the published literature on Thymosin Beta-4, it’s important to check which form was used. Studies using full Tβ4 cannot be assumed to translate directly to TB-500, and vice versa.
How TB-500 Works — The Mechanisms
TB-500’s primary mechanism involves actin — specifically G-actin, the monomeric form of actin that cells use to build and restructure their cytoskeleton.
The cytoskeleton is the internal scaffolding that gives cells their shape and enables them to move. When tissue is damaged, cells need to migrate toward the injury site, extend across the damaged area, and restructure themselves to rebuild what was lost. All of that movement depends on rapid and controlled actin polymerization — the assembly of individual G-actin monomers into F-actin filaments.
TB-500’s actin-binding activity essentially sequesters G-actin, keeping it available and regulating how it’s used. This sounds like a simple mechanism, but its downstream effects on cell behavior are extensive.
Cell Migration
By regulating actin dynamics, TB-500 promotes the kind of rapid, directional cell migration that is central to tissue repair. Cells need to reach injury sites quickly to begin the repair process, and the speed and efficiency of that migration is directly dependent on cytoskeletal dynamics. Fibroblasts, endothelial cells, keratinocytes, and other repair-relevant cell types all show enhanced migration in response to Thymosin Beta-4 in research models.
Angiogenesis
TB-500 has consistently shown pro-angiogenic activity in preclinical research — meaning it promotes the formation of new blood vessels. Damaged tissue loses its vascular supply. Without new vessel formation, the repair zone remains oxygen-deprived and nutrient-poor, which slows and limits the healing process. Thymosin Beta-4 upregulates several angiogenic signaling pathways, including interactions with VEGF (vascular endothelial growth factor) and laminin receptor pathways.
Anti-Fibrotic Activity — The Ac-SDKP Fragment
This is one of TB-500’s more clinically interesting properties from a research standpoint. During metabolism, Thymosin Beta-4 generates a tetrapeptide fragment called Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline). This fragment has demonstrated anti-fibrotic activity in multiple organ systems in animal research — particularly in cardiac, renal, and lung tissue.
Fibrosis — the excess deposition of scar tissue — is a major complication of chronic tissue injury. Scar tissue is less functional than the original tissue it replaces, and reducing excessive fibrosis improves the quality of the healed tissue. The Ac-SDKP pathway gives TB-500 a mechanism for influencing not just the speed of repair but the structural quality of the repaired tissue.
Anti-Inflammatory Signaling
TB-500 has shown activity on inflammatory pathways in multiple research models. It appears to suppress pro-inflammatory cytokines — particularly TNF-alpha and interleukins involved in the acute inflammatory response — and promotes the transition from inflammatory (M1) macrophages to repair-phase (M2) macrophages. This M1-to-M2 shift is a critical step in moving from the initial inflammatory phase of healing toward the proliferative repair phase.
Stem Cell Recruitment
More recent research has examined Thymosin Beta-4’s ability to activate cardiac progenitor cells and other tissue-specific stem cells, directing them toward injury sites. This mechanism is particularly relevant in the cardiac research context, where the heart’s limited regenerative capacity makes any compound capable of mobilizing progenitor cells scientifically significant.
What the Research Shows — Tissue by Tissue
Cardiac Research
This is arguably the most scientifically significant area of the TB-500 and Thymosin Beta-4 research base, and it’s worth spending time on because the findings here have driven substantial academic interest in the compound.
Multiple studies have examined Thymosin Beta-4 in cardiac ischemia models — essentially, what happens to heart tissue when blood supply is temporarily cut off, as occurs during a heart attack. The findings have shown that Tβ4 can activate epicardial progenitor cells — cells in the outer layer of the heart that normally remain dormant — and promote their differentiation into functional cardiomyocytes, the contractile cells of the heart muscle.
This is genuinely unusual. Heart muscle has extremely limited regenerative capacity. Most cells that die in a cardiac event are replaced by scar tissue rather than functional muscle. A compound that can mobilize progenitor cells toward functional cardiomyocyte differentiation represents a fundamentally different approach to cardiac repair biology.
Published studies in this area include work by Bock-Marquette and colleagues examining Thymosin Beta-4’s cardioprotective effects in mouse infarction models, and subsequent work examining the epicardial progenitor cell activation mechanism. The findings have been replicated across research groups and have generated substantial interest in the broader cardiac regeneration research community.
Muscle and Soft Tissue Research
TB-500’s actin-regulation mechanism is directly relevant to muscle fiber repair. Muscle fibers are composed of actin and myosin filaments — disrupting or damaging them requires reconstruction of the cytoskeletal architecture that actin dynamics control. Research in crush injury models and muscle laceration models has shown that Thymosin Beta-4 accelerates fiber repair, improves muscle organization, and reduces fibrotic scar formation within the repaired tissue.
Research has also examined TB-500 in tendon and ligament models, though BPC-157 has a more extensive evidence base specifically in tendon tissue. TB-500’s contribution in these models is considered more supportive — reducing inflammation and fibrosis, improving flexibility of the repaired tissue — rather than driving the primary repair response.
Wound Healing and Skin Research
One of the earliest and most consistent areas of Thymosin Beta-4 research involves wound healing and skin repair. Published studies dating back to the 1990s established its role in keratinocyte migration — the movement of skin cells across wound surfaces — which is the primary driver of wound closure.
Subsequent work has examined TB-500 in models of diabetic wound healing, burn injury, and surgical wound repair, consistently showing acceleration of wound closure and improvements in the organization of new tissue. The Ac-SDKP anti-fibrotic fragment is particularly relevant here, as it appears to reduce the degree of scarring compared to natural healing.
Neurological Research
The neurological research on Thymosin Beta-4 and TB-500 is less developed than the cardiac and wound healing literature but has been growing steadily. Studies have examined its activity in models of traumatic brain injury, spinal cord injury, and peripheral nerve damage.
The proposed mechanisms involve both the direct effect of actin regulation on neural cell migration and plasticity, and the indirect effect of angiogenesis on neural tissue viability — new blood vessel formation in damaged neural tissue improves oxygen and nutrient delivery to surviving cells.
Ocular Research
RGN-259, a formulation of full Thymosin Beta-4, has been examined in clinical trials for dry eye disease and corneal wound healing. While RGN-259 is not TB-500, this clinical research provides some translational context for the actin-binding fragment’s potential in ocular tissue models. TB-500 itself has appeared in preclinical ocular research examining corneal repair and tear film stability.
TB-500 vs. BPC-157 — The Key Research Distinction
These two compounds are frequently discussed together, often studied together, and sometimes confused for each other. They are genuinely different compounds with different mechanisms, different tissue distributions, and different research applications.
BPC-157 is a 15-amino acid peptide derived from a gastric protein. Its activity is primarily localized — it concentrates effects at or near the site of application rather than distributing throughout the body. Its mechanisms involve nitric oxide system modulation, VEGFR2 signaling, and fibroblast activity. Its strongest research applications are in tendon, ligament, and gastrointestinal tissue.
TB-500 works systemically. Its actin-regulation mechanism promotes cell migration from throughout the body toward injury sites — it doesn’t concentrate locally but mobilizes repair resources from a distance. Its strongest research applications include muscle, cardiac, and wound healing models, and its anti-fibrotic Ac-SDKP fragment gives it a distinct role in tissue quality.
The reason researchers frequently study both together is that they address different rate-limiting steps in the healing cascade. BPC-157 kicks off the local repair response; TB-500 provides systemic cell mobilization and anti-fibrotic activity. They are mechanistically complementary rather than redundant — which is the scientific rationale behind what the research community sometimes calls the Wolverine Stack.
For a complete comparison of these two compounds, see our BPC-157 vs TB-500 research guide.
TB-500 and the 2026 Regulatory Landscape
TB-500’s regulatory status has been moving through a significant transition in 2026 that researchers working with this compound should understand.
In late 2023, the FDA placed TB-500 on its Category 2 Bulk Drug Substances list, which blocked compounding pharmacies from preparing it for patients regardless of a physician’s prescription. This was part of a broader restriction affecting 19 commonly used research peptides.
On April 23, 2026, the FDA removed TB-500 from Category 2 following withdrawal of the original nomination. This is a meaningful development — the explicit prohibition on pharmacy compounding has been lifted — but it does not automatically authorize compounding pharmacies to prepare TB-500. Full authorization requires formal addition to the 503A Bulks List through the PCAC advisory process.
TB-500 is scheduled for evaluation at the FDA’s Pharmacy Compounding Advisory Committee meetings on July 23 and July 24, 2026, where the panel will review evidence and make recommendations on whether it should be eligible for legal pharmacy compounding. Those recommendations are not binding on the FDA, and formal rulemaking must follow before any reclassification takes legal effect.
For a full overview of the peptide regulatory landscape and what the 2026 developments actually mean, see our FDA Peptide Reclassification 2026 guide.
Research use: The Category 2 restriction and the reclassification process are pharmacy compounding regulations. They govern what licensed pharmacies can prepare for patients, not what research supply companies can provide to qualified researchers for legitimate laboratory investigation. TB-500 remains available for purchase for controlled scientific research under a “for research use only” framework.
Storage and Handling
TB-500 is supplied as lyophilized (freeze-dried) powder for research use. Proper storage and handling preserves compound integrity and ensures research results reflect the compound’s actual activity rather than degradation artifacts.
Lyophilized powder: Store at -20°C, protected from light and moisture. Stable for up to 24 months in appropriate storage conditions. Do not expose to repeated temperature fluctuations before reconstitution.
Reconstituted solution: Once reconstituted with bacteriostatic water, store at 2–8°C. Use within 28 days. Do not freeze reconstituted solutions — freeze-thaw cycling causes peptide aggregation that reduces the effective concentration in solution.
Handling: Handle under standard laboratory aseptic technique protocols. Reconstitute by running bacteriostatic water slowly down the inside wall of the vial rather than directly onto the powder cake. Allow 5 to 10 minutes of passive dissolution without agitation. Do not shake or vortex. A properly reconstituted TB-500 solution is completely transparent and colorless — cloudiness indicates aggregation or contamination and the vial should not be used.
Quality Standards for Research Use
The quality of research compounds directly affects the validity of research results. A peptide at 90% purity contains 10% unknown — in any experimental model, an observation could reflect the target compound’s activity or an impurity’s activity. Without controlled purity, results cannot be meaningfully interpreted.
Endotoxin contamination is a separate concern that purity testing alone doesn’t address. A peptide can test at 99% purity by HPLC and still contain significant levels of bacterial lipopolysaccharide contamination from manufacturing. Endotoxin triggers inflammatory responses in biological research models that have nothing to do with the compound being studied — it’s one of the most common confounders in preclinical research using synthetic peptides.
The testing standard that research integrity requires includes all four of the following, conducted by a laboratory independent of the manufacturer:
HPLC purity analysis — confirming the target compound constitutes at least 99% of the sample. Mass spectrometry identity verification — confirming the compound’s molecular weight and fragmentation pattern match TB-500’s known profile. Endotoxin screening — confirming bacterial contamination is below research-applicable thresholds. Sterility testing — confirming absence of bacterial and fungal contamination.
All Patriot Peptides TB-500 (5mg) is manufactured in a cGMP-certified US facility and independently tested by certified third-party laboratories across all four criteria. Batch-specific Certificates of Analysis are available for every product.
Frequently Asked Questions
What is TB-500? TB-500 is a synthetic 7-amino acid peptide corresponding to the actin-binding domain of Thymosin Beta-4, a naturally occurring 43-amino acid protein present in virtually all nucleated cells. The specific fragment — Ac-LKKTETQ — is studied in research for its roles in cell migration, angiogenesis, and tissue repair. It is supplied as lyophilized powder for laboratory research use only.
Is TB-500 the same as Thymosin Beta-4? No. Thymosin Beta-4 is a 43-amino acid protein that occurs naturally in the human body. TB-500 is a synthetic 7-amino acid fragment corresponding to amino acids 17 through 23 of that protein — specifically the actin-binding domain. TB-500 retains the primary actin-regulatory activity of the parent molecule but is not chemically identical to it.
How does TB-500 work? TB-500’s primary mechanism involves binding to G-actin, the monomeric building block of the actin cytoskeleton, which regulates cell migration, shape, and movement. This promotes the rapid cell migration toward injury sites that drives tissue repair. Secondary mechanisms include pro-angiogenic signaling, anti-inflammatory cytokine modulation, and anti-fibrotic activity through its Ac-SDKP metabolic fragment.
What is TB-500 studied for in research? TB-500 is studied across a broad range of tissue types including cardiac tissue, muscle and soft tissue, wound healing and skin models, tendon and ligament, and neurological models. Its systemic distribution pattern — it works body-wide rather than concentrating locally — makes it particularly relevant in research involving widespread tissue damage or multiple injury sites.
How is TB-500 different from BPC-157? BPC-157 works primarily through localized tissue signaling, concentrating effects at or near the application site through NO system modulation and VEGFR2 signaling. TB-500 works systemically through actin regulation, mobilizing cell migration from throughout the body toward injury sites. They address different mechanistic steps in tissue repair and are often studied together for that reason.
What form does TB-500 come in for research? TB-500 is supplied as lyophilized (freeze-dried) powder in sterile glass vials. It requires reconstitution with bacteriostatic water before use in research protocols.
Is TB-500 legal to purchase in the USA? TB-500 can be purchased for legitimate laboratory research purposes under a research use only framework. As of April 23, 2026, it was removed from the FDA’s Category 2 restricted compounding list. The PCAC is scheduled to evaluate it for 503A Bulks List inclusion at meetings on July 23 and 24, 2026. For a full regulatory overview, see our FDA Peptide Reclassification 2026 guide.
Where can I buy research-grade TB-500? Patriot Peptides TB-500 (5mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility. Batch-specific Certificates of Analysis are available. For laboratory research use only.
All content is for informational and educational purposes only. All Patriot Peptides products are strictly for laboratory research use only. Not for human consumption, veterinary use, or clinical application.
Related: BPC-157 vs TB-500: Complete Research Comparison | What Is BPC-157? | How to Reconstitute BPC-157 | FDA Peptide Reclassification 2026